Verastem Inc (VSTM) reports significant revenue growth and FDA approval, but faces hurdles with NCCN guidelines and financial losses.

Moby Strategic Execution and Portfolio Prioritization. Achieved $30.9 million in net product revenue since the May 2025 launch of AV ...

Long-Term Follow-Up of Real-World Adjuvant Anti–PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III Melanoma In this phase II, open-label study, patients with recurrent, ...

The firm received FDA feedback on the design of registrational studies of VS-7375, while it awaits new data for Avmapki Fakzynja.

The current quarter saw explicit confirmation of the CO-PACK franchise’s path to self-sustainability in H2 2026 and an extension of the cash runway into H1 2027, compared to the prior quarter’s ...

Avutometinib and defactinib combination shows over one-year median PFS in recurrent LGSOC patients, with notable efficacy in KRAS-mutant and KRAS-wild-type populations. Verastem Oncology plans FDA ...

CHICAGO -- Adding an EGFR inhibitor to chemotherapy significantly improved overall survival (OS) in advanced KRAS wild-type pancreatic cancer, a randomized trial showed. Median OS improved from 8.5 ...

Gut microbiota signatures associated with KRAS mutations in patients with colorectal cancer (CRC) have been identified by researchers. Their findings suggest that the gut microbes may serve as ...